Okay. Beth. joining Good everyone for call. you, you and Thank thank afternoon, our
but reported best the revenue from quarters. numbers. QX was our about losses comments encouraging QX an were XX reduced, Beth that quarter already our just dramatically perspective, our has past in First, a
non-binding as with sheet undoubtedly amends two agreement of week aware, term TheraCann are cooperation our a last licensing that companies. all between the and Now, you exclusive DNA Applied announced
Just and the X-K filed continued prior an on to the of status we NASDAQ. that, our listing
sheet questions. announced call your update us of developments I'll by non-binding activities due term are these in verticals cash under the then these Now X about significant the $X summarize in million and to of in call agreement. To last the open they key start I'll the how talking given intertwined. our today's the you developments. on TheraCann week I before to lieu
note preferred convertible upon a our $X signing us agreement. of agreement, provide a the convertible $X will stock original adding the $X TheraCann benefit million promissory in definitive and million to worth million
Beth the us already reviewed for Now has details. financial
TheraCann two with agreed to cooperation agreement licensing reasons. and amend our for We've
our of to million received cash partner. is in DNA. the First, in support total to shareholders obligation their the our it term we benefit cannabis and QX Applied of Applied dollars that DNA long exclusive first We
cannabis is trace the We years, use track This DNA original of the BioTrace. tag from chain developed trace two the cannabis in control past and any solution ETCH contract property as sell seed at $X diversion known point under we've the to standard supply to auspices system million over believe our R&D now intellectual and ability of the that powers a TheraCann TheraCann. control. gold to system Now and
to expansion relationship. pipeline industry. bring negotiating impress top Applied witnessed is the It they of TheraCann for marketplace is continues the very that a table. cannabis DNA with TheraCann's to ETCH business powered by customers BioTrace our in the tier have the We us since start agrees clear the gamechanger us firsthand to the that
Toronto the has disruptive on confirm In Leadership with fact, week. for of supporting Executive listing TSXV the operations expanding the pursuing meeting completed Thursday TheraCann yesterday and this Council pipeline, the hemp on and review that TSXV. is technology their a industry, this Exchange basis that learned the cannabis portfolio and on their Venture is We Stock global it of
payment the listing half way in TheraCann's days $X pave our the to accrued term following few to That stock according of to the the the us TheraCann demand would a preferred which in sheet the of dividends. thereafter, for second should million September, of our amended plus result redemption
of equity. Now their to issuance preferred second, equity our increases shareholders us TheraCann's
As requirement meet the of us considered cure maintain under is million this licensing it to our more NASDAQ minimum We'll important by threshold to deficiencies our payment helps about because required $X approach the it our that have and in is moment. agreements, one listing. equity and a
in has faith partners they our our of our have all wavered. summary, TheraCann throughout in in been and good negotiation. mutual And stages never development So
We say later business will remarks. our to in cannabis my TheraCann more have about in
NASDAQ Beth warrants noted, two Hearings NASDAQ with listing August we effective based XX, and staff notice with had stating received traded if the our to had the our our requested NASDAQ Panel. we NASDAQ non-compliance continued July the As delist that a not X, listing, rules, regarding hearing on publicly shares NASDAQ the from Now determined on
delisting And NASDAQ the date we September it appeal XX we have Hearings Panel the right to our that requested a I Well, assigned starts am to have present is report the process hearings listed been hearing company. as to the pleased all a NASDAQ before panel. that of as
after the trade The the are The for be XX to decision panel hearing, on has be and continued the sooner. panel to generally NASDAQ. the In company delist meantime, issues authority will continue could our allow the however, warrants shares within received written days or the decision listings. the
market on capitalization As the requires with discussed Beth investor $XX companies calls, listing rule, a million. minimum we to prior non-compliant of are which have
me threshold stockholders $X.XX, by this in can $XX cap cured a be of equity our by above breach or equity $X.X and as market a then gets the passing above $X of thereafter. price excuse However, either share million, stockholders million, which of minimum maintaining, return million
stockholders the signing We and equity. deficiency TheraCann plan shareholder Under for with have developed added our sheets are a NASDAQ equity and preferred sheet liquidity a we company's the balance definitive and of we our to the to on and upon will cure shares. multiphase the standard executing million this listing minimum receipt as have balance improve of $X plan, agreement
terms our a current the listings debt further equity. amended also their and as notes convertible Doing have of into raise to holders would We so step equity compliance. the to convert achieving in incense our note shareholders
in of the Vitatex grew Now by equity assets our shareholders $XXX,XXX. approximately acquisition of also
taking we XX. between and We'll be today the disclosed public via releases. will be Additional September steps press and filings
should we would company's definitive Finally, TheraCann to and be best QX that being the it history. signed, note shares issued in in the the agreement is result revenue if preferred the the with quarter September prior XX,
we million expect $X upon to of would EBITDA have addition the With revenue QX definitive the of well. agreement, positive in of as signing
absolute imperative. an is listing NASDAQ our clear, be me corporate let So
our and during focus textiles and to stated and thereafter. Now, and as QX, platform, continue molecular monetize our we with tagging diagnostic LineaRx particular platforms cannabis last I therapeutic quarter, on
update will forward. me key across verticals our Let growth on catalyze our progress you that going
our Now textiles, for we global prospects business. see apparel in addition plan about whose to textiles, This to to of homes the optimistic cotton. began our us comprise we're very year, with growth cotton our for foundation
pimi Himatsingka demand with Now ginning steady beginning have drumbeat. and at introduction of the for a our seasons. licensee in America, cotton new October, partners us steady bringing coming senior home expansions time a upcoming products. of development The cotton market new continues this our is textiles this At the communicated for exclusive [ph] season management
is that soon shaped, will less still to us. clear homegrown being for be communicated products the demand While
first shortly. We just expect runs. manufacturing And orders our we preparing are
have with Egyptian Himatsingka to of We the expand worked partners diligently market new with our tagging addressable cotton.
In cotton be partners, local shipped Egyptian generate During System with Signature QX, Cairo. a markets. extra-long tagged and while training to to July, to outside contracts and European was implementation of demand Egyptian gin Himatsingka shored and cotton demonstration in quantity of up a DNA Transfer our to we U.S. converted DNA products staple
a Now, all we kudos are monitoring, dale involved the to for this where enthusiastic quality become Egyptian brought of traceability. It to gin serialization, partners remote cotton our included initiative, dale we who this and DNA this to scanning, infrastructure of in part solution cotton market. hear should signature that supply before this now more internet is alerts, at access so with through email in time, with traveling from long. The marketplace tag the uniquely marked chain cotton this complete
increased a more are use movements. market outdoor Now apparel cotton. thanks of synthetic diverse fashion broadly, in textiles has to synthetic apparel the than and much the Demand fast larger, materials fitness and in
by led it. hard technical India, by experienced are all We and worth sales that But supply team, aided has the integrating expense complex China, work chains. over been Taiwan crew a and prior operations an travelled has
PET, feather, provide are multiple leather, recycled viscos and we end-to-end announcing in to additives, As synthetics. down platform our traceability begin to material integrate other categories, brands certainty including and coatings wool, and specialty
supply brands effective, sustainability intend flexible chains communicate best transparency enable inspire sustainable. to best traceability through to As their end can reinforce loyalty fit Only one and traceability platform, consumer. trust and are they how retailers retailers supply that their and utilize our and to the and and fulfill brand to and can tools them brands goals and confidence cost
and story, retailers approach helps identity ahead products this compelling, group tell great strategic consumers. that by see large and vertical. the both end We need scale to preservation growing to structure all sustainable, The of brands authentic proportion to and taken support of responsible for things that really textiles deployment also develop the the a meaningful traceable our is
Regulatory ladder the being pharmaceuticals. cannabis of we and supplements skincare nutritional complexity the a regulated products make to and used nutraceutical, our textiles, move as diversity of increases and the Now us from roadmap hemp, regulated to to most. non-cannabis, from least to takes food,
make We continue markets. progress the in to regulated world of
our on regulated most longest shortest executing to corresponds to least market. continue We and the roughly the from and roadmap, time that
the so which comprehensive market core good intent testing attest. that is to only is ready versions In stability our with extensive pharma, a is continues that products. time. good testing Colorcon and Colorcon's work to this times But can all for not extended our requires Opdry news news of with be The
family all we've is to of ability to XX% track on about Now represents stability product this that pharmaceutics on leveraging its testing trace that date dose completed Colorcon product and the one offer portfolio. Colorcon supply capabilities. and
more XX% In to effect, on Colorcon pharmaceutical from us Colorcon. is of to leveraging give platform our profile manufacturers we more raise the pursuing to with portfolio to remaining material generate win its And now goal are shots business. their revenues
on store have solution forensic goal for organization the been that's capability occur. an tagging brand on patented already nutraceuticals, its should for validation with product This is a ever we a it In of product of the firms of adulteration and protection development working legal shelves. evidence with marketed
and completed a have lab We trial feasibility run. production studies
final trial its in it successful, scale will result incorporation to XXXX. this are We in already in preparation early products for their commercial month and
TheraCann’s at that Now, firsthand XXXX. Statista to billion over remarks, we the witnessed set the $XX by is expansion relationship. XXXX, reported of business market in since our cannabis I legal stated as global of reach value start in The pipeline, start by the
out We with build continue pipeline the globe. opportunities to across of TheraCann our
size has up detailed been funnel discussions entities. in horizons. and The lining having long next various with The medium industry with technical us quarters. potential mix team scope, significant especially pilots opportunities pre levels, short, these with front demand larger opportunities a are and over at maturity of meeting has commercial the of significant several Our and global in the players,
to brand THC is The and from CBD interest and snapshot our processors materials provide Oceana a the entities, are verification across level protect angles sample Europe, Latin America, and of spread is XX original their value source government of Africa. to North their both opportunities, raw from cultivators, finished still products. The the with biomass coming for we IP, focus still pursuing you and multiple and products. Just Asia, proposition America, on
The pursuits as our catalyzed states in of by regulatory, that publicly pipeline House those CannAcubed, also announced level and regulation commercial of But U.S. of Cannabis and track individual the opportunities Israel the and such marries centered trace authenticity at that have both been on and Hemp.
As central the those product the becomes plan. ability for their the participants industry differentiate matures from to their and of competitors their of ecosystem pillar business scales,
a from specific who and want their As cultivated their in marketplace. counterfeiters an has product will content example, a low THC to protect IP grower defend
of initial to to with target would each if graduate have the sight customer. stage line associated revenue We scale development that activities with successful, opportunities commercial
As applied industry consumer by are and of and scale, matures regulatory the ETCH internationally, the domestically safety. TheraCann DNA we at positioning supply cannabis both and chain sit to powered certainty BioTrace and nexus compliance,
since Now LineaRx. the over launch you profile October. past biotechnology the LineaRx volume news several from last our owned subsidiary to the related majority The turning us our of have industry, seen correlates growing of to months within
diagnostics acquisition forward and a IP have short months, the platform. interest of in these assets have we of profile. accelerating just taken And therapeutics we seen substantial with XX raising week, leap last already In in our Vitatex and elevated our an
is biotech taken think really marketplace notice. fair in I leaders it the the that say to have
which risks, of the to of platform of to the arrival single all produced for opportunity eliminate. is decades. of gene therapy were for of the the linear Plasmids LineaRx. estimate. and by with comes The plasmids holds research almost and source are DNA LineaRx form routine replace market until us every key And has singular they our have use viruses, backbone the us, PCR in multiple therapy. to of large they the too potential gene deliver genetic DNA Plasmid of nearly manufacturer
the the diagnostic In increased therapeutic and saw QX, components business. of we in LineaRx activity
Applied the side, of diagnostics a the shipped quarterly shipments diagnostics that total an existing to we in invitro annually customer to should LineaRx. quarterly the four revenue the be market. and $XXX,XXX from shipments eventually will These On first over moved DNA's
expected that which revenue These developing customer. a customer, same market will so happy assays through expected custom are that are very drive to applicants of applicants for our to chain. In be addition you that come supply are you increase to Excuse to new know new components XXXX, existing we me. in shipment, have
used On including including should linear Services receive gene developers we cell the and side, the will DNA for approval of by applications, preclinical and these Centers marquee therapeutic purchase The increase some It's and that therapies, therapies development be Medicaid for orders will across a recent therapeutic that for multiple size CAR-T. rapidly. reimbursement provide companies. variety noting orders Medicare CAR-T worth approved the from market the
regarding of support coming Eagle orders, to Our was Eagle the in number efforts DNA benefits shipment to of of and their research therapy to developers placing a of linear growing quantity evaluate in is Tech research disease. development Huntington's therapeutic representative Tech Linea pipeline. LineaRx
stronger Blood Hematology importantly orders at producing potential the an even are applications perspective. CAR-T linear therapies. growth a for expected use over we The and is the and are related University We purchase therapeutic to of deliver DNA and for for strong seeing more Institute QX, interest QX year-over-year in Transfusion and revenue Prague growth from in diagnostic both
revenue in orders and from we addition year. to drive will therapies. the are growth the key first vaccine expecting CAR-T in These half orders revenue XXXX RNA additional of developers In QX,
that allows in or can our circulating can be very used diagnosis aligns immuno-oncology. Vitatex Now we or cells, a Vitatex as late general early used DNA brought capacity in tumor within to us generate perfectly diagnosis LineaRx, isolate be with invasive in and diagnostic. Vitatex, which to
a it immune cells the universe become on on the platform in a are blood in cancer. therapies, unique metastasizing patient's When treat this CAR-T the Our force cancers within to that our their personalized tube therapies DNA, entire cell of to unique because produce custom we based a that is of engineering own development with mass of functional combined aspect, cells. behavior ability relies mimics formidable
we entered throughout a the to that reverberations affect of on ground the holds acquisition, potential With this technology floor believe immuno-oncology. we
grants contracts acquisition our of As IP, reason for company. that are an an such example stage of assets key to its line and of and a for early sight Vitatex impressive its has potential and
financial of pre-money not that last million. given stages in that valuation $XX early raise was years two the ago it's worth in a some But Vitatex it noting of all excess
to join We have our them are fortunate team. very
in revenue challenges. growth focused our them. we opportunities cannabis, time, remain conclusion, textiles shareholders support long Biotherapeutics near aggressively very higher across Biotherapeutics offers that the to will in near in have executing particular, believe the compelling At on our So we moving We're and term path a overcome same term. on and to value. we
this Operator, questions. open concludes remarks. Now my the call to please prepared
